AGC Biologics supports manufacturing of Omicron-based candidate vaccines with starting material

CDMO’s global Heidelberg facility provides more pDNA material to help meet growing needs

Heidelberg, Germany, February 08, 2022 (GLOBE NEWSWIRE) — AGC Organic Productsa global biopharmaceutical contract development and manufacturing organization (CDMO), today announced an expanded partnership to provide more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at company facilities in Heidelberg.

According to a recent press release from Pfizer and BioNTech, the companies have begun developing an Omicron-based COVID-19 vaccine, with the first batches expected to be ready for delivery by the end of March 2022.

“We are proud to continue to support BioNTech and provide them with pDNA materials for their vaccine production, in the fight against new pandemic variants,” said Patricio Massera, CEO of AGC Biologics. “Our pDNA services are part of our growing global cell and gene therapy offering which includes the development and manufacturing of cell therapies, viral vectors and messenger RNA.”

“This kind of work is what motivates us every day,” says Dieter Kramer, Managing Director of AGC Biologics, Heidelberg. “We appreciate this opportunity to help make a difference in the lives of people around the world and to produce life-saving treatments.”

The AGC Biologics Heidelberg factory has over 20 years of experience in providing a wide range of programs for customers. The site is the company’s center of excellence for pDNA production and a central part of AGC Biologics’ global network of cell and gene therapy-focused facilities, with additional sites in Milan, Italy, and in Longmont, Colorado, USA.

For more information on AGC Biologics’ plasmid DNA offering, visit To learn more about the company’s broader cell and gene therapy services, visit

About AGC Biologics
AGC Biologics is a global biopharmaceutical contract development and manufacturing organization (CDMO) with a strong commitment to providing the highest level of service as we work side-by-side with our customers and partners, every step of the way. We provide world-class development and manufacturing of mammalian and microbial therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors and genetically engineered cells. Our global network spans the United States, Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and currently employ over 2,000 employees worldwide. Our commitment to continuous innovation fosters technical creativity to solve our customers’ most complex challenges, including specialization in fast track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit

Nick McDonald AGC Biologics (425) 419-3555 [email protected] 

Comments are closed.